Marval advises on BD’s global spin-off

Marval O’Farrell Mairal advised Becton, Dickinson and Company ("BD"), one of the largest global medical technology companies, on the Argentine law aspects of the global spin-off of its Biosciences & Diagnostic Solutions business. Immediately following the spin-off, the spun-off entity was combined with Waters Corporation to create a global life sciences and diagnostics leader dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. The transaction was structured as a Reverse Morris Trust transaction valued at approximately US$18.8 billion and closed in most countries on February 9, 2026, and in Argentina, along with other countries, on April 1, 2026.

Biosciences is a leader in immunology and cancer research solutions and related clinical diagnostics, including flow cytometry instruments and reagents, and innovative multiomics tools. Diagnostic Solutions is a leader in microbiology and infectious disease diagnostics, including molecular diagnostics, cervical cancer screening, microbiology automation, and point-of-care offerings. For calendar year 2025, BD’s Biosciences & Diagnostic Solutions business was expected to generate revenue of approximately US$3.4 billion.

The Marval O’Farrell Mairal team advising BD was led by partner Diego Krischcautzky and comprised associates Mariano Martín Morat and Santiago Cassina.

marval.com